The currently established nomenclature for psychotropic drugs is outdated and no longer reflects the progress of neuroscience. In response to this situation, the Neuroscience-based Nomenclature (NbN) was developed: A system for the classification of psychotropic drugs, which brings important advantages for patients, clinicians, and researchers. The German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN) supports the introduction of the NbN in care, science, and teaching.
The DGPPN actively campaigns for the participation of people with mental illness in society and against their stigmatization. We are committed to respecting the dignity and the right of self-determination of service users and support them irrespective of gender, skin colour, religion or social background. In the light of the history of psychiatry, DGPPN is committed to the principles of diversity and inclusion.